We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Primary Care

News · January 31, 2021

J&J COVID-19 Vaccine 66 Percent Effective in Interim Analysis

Efficacy varies by region, with 57 percent efficacy in South Africa and 72 percent efficacy in the United States



Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading